We're pleased to host the Women in Cancer Research (WICR) Council today. The WICR Council advises AACR leadership on issues of concern to women investigators and fosters career development to create a more equitable cancer workforce. https://t.co/RziC7Zh8II #AACRWICR
We are just one week away from the abstract deadline for the ISMRM Brain Function Workshop in Padua (https://t.co/JxgBT6CiHd), during which the non-BOLD fMRI session will feature Nan Li (@NaNeuroimage) presenting "Molecular fMRI - Mapping Brain Neurochemical Events In-Vivo!"
Join clinicians from around the world at the 22nd Annual #InternationalBreastCancerCongress to discuss cutting edge treatments, data, and approaches that are driving the future of breast cancer therapy.
📆14-15 July
👉https://t.co/uruxFak52d
#MedEd#oncology
It was a pleasure to deliver a keynote presentation at the @VisualSonics Symposium at @Georgetown yesterday! Thanks to the organizers and hosts for warmly welcoming me as one of the newest customers and users of the Vevo product family.
Are you a skilled computational scientist with background in single cell & NGS pipelines?
Join our team! @brunklab and @PSpanheimer
Get involved on projects where precision medicine meets genome science!
90-100K, great benefits, remote possible:
https://t.co/U9ROHZdKgB
Abstract 1020: Exploratory biomarker analysis of DestinyBreast04
✅ TDxd was superior to TPC in all subgroups including different intrinsic subtypes, ESR1, PIK3CA!
#bcsm@OncBrothers@OncoAlert
🆕 Just presented by Nadia Harbeck at #ASCO23 , results of the PreCycle randomized ph IV study, a multicenter eHealth trial testing the CANKADO app in patients with HR+/HER2- MBC treated with oral drugs, are simultaneously available #openaccess 👉 https://t.co/qggI9uOsGQ #bcsm
The power of @theNCI#NCTN - with 2 studies presented in the @ASCO Plenary. Federally Funded Clinical Trials Change Lives ‼️- Congratulations @SWOG@ALLIANCE_org#COG 👏
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). @stolaney1
Summary: https://t.co/EhtJ4vYzX0
#ASCO23#bcsm
Fixed dose of 1500mg capecitabine BID 7on/7off schedule had similar efficacy to BSA schedule 14on/7off in MBC
⬇️ incidence of diarrhea, HFS & stomatitis
⬇️treatment modifications and discontinuations
🙌🏼 to alternative dosing with less toxicity
#bcsm#ASCO23@OncoAlert
Our very own dream team. UNC Lineberger’s breast cancer program is well represented at the #ASCO23 annual meeting: @guptalabunc, @YAbdouMD, @DrLisaCarey Emily Ray, and Katie Reeder-Hayes.
Submit an abstract by August 3 for the AACR Special Conference on Advances in Breast Cancer Research (October 19-22, San Diego), chaired by Jason S. Carroll, @JennyCChang1, and Jane E. Visvader. Learn more:
https://t.co/chZrjX5HCU
#AACRbc23@JCarrollLab
#DataMatters 2023 will take place virtually from August 7 - 11. The week-long series of short courses for students and professionals in business, research, and government is a great way to learn about all things #datascience. #dataanalytics#programming
https://t.co/FfxsV3x1gN